#USA #New York #FDA #Pomerantz Law Firm #PepGen Inc.

Pomerantz Law Firm Investigates PepGen Inc.

Pomerantz LLP, a well-known law firm specializing in corporate and securities class actions, has announced its investigation into claims concerning PepGen Inc. (NASDAQ: PEPG). This investigation is particularly relevant for investors who may have suffered losses related to the company's business practices, especially considering recent disclosures that have shaken investor confidence.

Background on the Investigation

On March 4, 2026, PepGen disclosed that the U.S. Food and Drug Administration (FDA) had placed a partial clinical hold on its FREEDOM2-DM1 Phase 2 clinical trial. This trial is pivotal as it evaluates the safety and efficacy of the company's drug PGN-EDODM1 for treating myotonic dystrophy type 1 (DM1). The FDA's concerns centered on previously submitted preclinical pharmacology and toxicology studies. As a result of this announcement, PepGen's stock plummeted by $1.25 per share, equating to an 18.57% drop, leaving the stock at $5.50 per share by the market close on March 5, 2026.

The investigation aims to uncover whether PepGen and any of its executives engaged in activities that could constitute securities fraud, as well as other potentially unlawful business practices. This case underscores the critical nature of transparency and accountability in the biotech sector, particularly when patient health, investor credibility, and market confidence are at stake.

The Role of Pomerantz LLP

Pomerantz has a long-standing reputation in the legal community, especially in cases involving corporate misconduct and fraud. Founded by Abraham L. Pomerantz, the firm has been at the forefront of securities class actions for over 85 years. The law firm takes pride in advocating for investors and has successfully recovered significant damages for clients affected by corporate wrongdoing. The firm’s commitment to safeguarding investor rights makes it a vital player in navigating the complexities of securities litigation.

The firm encourages affected investors to come forward to share their experiences. They can do so by contacting Danielle Peyton at Pomerantz LLP through the provided email or phone number, signaling a proactive approach to address investor concerns and potential claims.

Implications for Investors

The implications of these developments for PepGen investors could be significant. The partial clinical hold raises questions about the company's drug development pipeline and future clinical trials. For investors, this means closely monitoring the situation and weighing the risks associated with their investments in PepGen. The volatility observed post-announcement suggests that investors should stay informed and consider their options carefully.

In conclusion, the Pomerantz investigation into PepGen not only highlights the importance of corporate governance in the biotech field but also serves as a reminder for investors to remain vigilant regarding the financial health and ethical practices of the companies in which they hold shares. With the possibility of a class action being formed, the outcome of this investigation could hold meaningful consequences for all parties involved.

For more updates and to join the class action, investors are encouraged to engage with the legal team at Pomerantz LLP to ensure their voices are heard in this critical period.